Switch theme
Sign up to access all valuation multiples
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.
2002
7
Last FY Revenue n/a
LTM EBITDA -$16.8M
$15.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Grace Therapeutics has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$16.8M.
In the most recent fiscal year, Grace Therapeutics achieved revenue of n/a and an EBITDA of -$11.3M.
Grace Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Grace Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$16.8M | XXX | -$11.3M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$17.1M | XXX | -$11.4M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$14.3M | XXX | -$12.9M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Grace Therapeutics's stock price is $3.
Grace Therapeutics has current market cap of $38.0M, and EV of $15.0M.
See Grace Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $15.0M | $38.0M | XXX | XXX | XXX | XXX | $-1.13 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Grace Therapeutics has market cap of $38.0M and EV of $15.0M.
Grace Therapeutics's trades at n/a EV/Revenue multiple, and -1.0x EV/EBITDA.
Equity research analysts estimate Grace Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Grace Therapeutics has a P/E ratio of -2.7x.
See valuation multiples for Grace Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $38.0M | XXX | $38.0M | XXX | XXX | XXX |
| EV (current) | $15.0M | XXX | $15.0M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -0.9x | XXX | -1.0x | XXX | XXX | XXX |
| EV/EBIT | -0.9x | XXX | -1.0x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.7x | XXX | -2.8x | XXX | XXX | XXX |
| EV/FCF | -0.9x | XXX | -1.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGrace Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.6M for the same period.
Grace Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Grace Therapeutics's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Grace Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -4% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Grace Therapeutics acquired XXX companies to date.
Last acquisition by Grace Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Grace Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Grace Therapeutics founded? | Grace Therapeutics was founded in 2002. |
| Where is Grace Therapeutics headquartered? | Grace Therapeutics is headquartered in United States of America. |
| How many employees does Grace Therapeutics have? | As of today, Grace Therapeutics has 7 employees. |
| Who is the CEO of Grace Therapeutics? | Grace Therapeutics's CEO is Mr. Prashant Kohli. |
| Is Grace Therapeutics publicy listed? | Yes, Grace Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Grace Therapeutics? | Grace Therapeutics trades under GRCE ticker. |
| When did Grace Therapeutics go public? | Grace Therapeutics went public in 2011. |
| Who are competitors of Grace Therapeutics? | Similar companies to Grace Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Grace Therapeutics? | Grace Therapeutics's current market cap is $38.0M |
| Is Grace Therapeutics profitable? | Yes, Grace Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Grace Therapeutics? | Grace Therapeutics's last 12 months EBITDA is -$16.8M. |
| What is the current EV/EBITDA multiple of Grace Therapeutics? | Current EBITDA multiple of Grace Therapeutics is -0.9x. |
| What is the current FCF of Grace Therapeutics? | Grace Therapeutics's last 12 months FCF is -$15.9M. |
| What is the current EV/FCF multiple of Grace Therapeutics? | Current FCF multiple of Grace Therapeutics is -0.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
